Related to this topic: Patient+ | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Apolipoproteins

Synonym: apoprotein
Lipoproteins are complexes of lipid and protein, whose main function is to transport lipids. Apolipoproteins are proteins found in the external phospholipid layer of the lipoproteins. Apolipoproteins are important in maintaining the structural integrity and solubility of lipoproteins, play an important role in lipoprotein receptor recognition and also the regulation of certain enzymes in lipoprotein metabolism. There are many different apolipoproteins, including:

  • Apo A1: the major apoprotein of HDL and is a relatively abundant plasma protein1
  • Apo B: the main apolipoprotein of chylomicrons and low density lipoproteins2
    • Apolipoprotein B is a measurement of the total number of atherogenic particles and is therefore thought to be a better marker of risk of vascular disease and a better guide to the adequacy of statin treatment than any cholesterol index3
    • The ratio of apolipoprotein B/apolipoprotein A-1 seems superior to the ratio of total cholesterol/HDL cholesterol as an overall index of the risk of vascular disease3
    • Apo B and the apo B/apo A1 ratio have been shown to be predictive of ischaemic stroke in patients with previous TIA4
  • Apo CII: activates lipoprotein lipase in capillaries, liberating fatty acids and monoglycerides from chylomicrons, with the fatty acids then passing into adipocytes or muscle5
  • Apo CIII: an antagonist of plasma triglyceride catabolism; increased apo C-III expression may lead to hypertriglyceridaemia and an atherogenic lipoprotein profile6
  • D: a protein component of high-density lipoprotein in human plasma7
  • E: involved in receptor recognition of intermediate density lipoprotein and chylomicron remnant by the liver:
    • In familial dysbetalipoproteinaemia, increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants because of a defect in apolipoprotein E8
    • There is thought to be an association between apolipoprotein E and neurodegenerative conditions such as multiple sclerosis and Alzheimer's disease9. Apolipoprotein E4 variant increases the risk of Alzheimer's disease presenting at an earlier age.
Apolipoprotein disorders

Specific apolipoprotein disorders are rare but there is increasing knowledge and awareness as to the importance of apolipoproteins and their relevance to a variety of clinical disorders. Two of the most important specific apolipoprotein disorders are apoC-II deficiency and familial defective apoprotein B.

Apo-C-II deficiency:

  • Rare autosomal recessive hereditary disorder
  • Apolipoprotein C-II (apoC-II) activates lipoprotein lipase and so there is an overlap between lipoprotein lipase deficiency and apolipoprotein C-II deficiency
  • Deficiency of apolipoprotein C-II leads to an accumulation of chylomicrons and triglycerides
  • Xanthomas and hepatosplenomegaly are less common in apoC-II deficiency than in lipoprotein lipase deficiency
  • Diagnosis is by absence of apoC-II by protein electrophoresis
  • Mainstay of treatment is a fat-free diet.

Familial defective apoprotein B-100:

  • Autosomal dominant disorder involving a mutation of apo B that interferes with binding of LDL
  • Total cholesterol and LDL-cholesterol levels are raised and triglyceride levels are normal
  • Clinical presentation is very similar to familial hypercholesterolaemia. It has been estimated that up to 4% of patients with clinical familial hypercholesterolaemia may have familial defective apo B.

Document References
  1. OMIM; Apolipoprotien A-1
  2. OMIM; Apolipoprotein B
  3. Sniderman AD, Furberg CD, Keech A, et al; Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment.; Lancet. 2003 Mar 1;361(9359):777-80.
  4. Bhatia M, Howard SC, Clark TG, et al; Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack.; Cerebrovasc Dis. 2006;21(5-6):323-8. Epub 2006 Feb 14. [abstract]
  5. OMIM; Apolipoprotein C-II
  6. OMIM; Apolipoprotein C-III
  7. OMIM; Apolipoprotein D
  8. OMIM; Apolipoprotein E
  9. Fazekas F, Enzinger C, Ropele S, et al; The impact of our genes: consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosis.; J Neurol Sci. 2006 Jun 15;245(1-2):35-9. Epub 2006 Apr 24. [abstract]
Acknowledgements EMIS is grateful to Dr Colin Tidy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 1523
Document Version: 20
DocRef: bgp25311
Last Updated: 6 Dec 2006
Review Date: 5 Dec 2008
Patient UK Current Health News








Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site




Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page